Biosimilars of eculizumab, which have the potential to reduce costs for both patients and the healthcare system, have been eagerly awaited, yet many drug makers are developing novel anti-C5 agents.
Patents covering eculizumab (Soliris) are set to expire in the United States and Europe within the next 3 years, and with biosimilar competition looming for the innovator drug that binds to the C5 complement protein, Alexion Pharmaceuticals may have found a way to retain its share of the market for treatments targeting paroxysmal nocturnal hemoglobinuria (PNH). Yesterday, the drug maker announced pivotal phase 3 data from a study of a new longer-acting C5 complement inhibitor, ALXN1210.
PNH is an ultra-rare blood disorder that causes uncontrolled activation of the complement system and results in hemolysis, the destruction of red blood cells, which in turn can cause thrombosis.
The study, says Alexion, demonstrated the noninferiority of the longer-acting ALXN1210 to eculizumab in patients with PNH who had not been previously treated with a complement inhibitor. The study of ALXN1210 met its co-primary end points of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels.
The investigational drug also demonstrated noninferiority to eculizumab in all 4 key secondary end points: the percentage change from baseline in LDH levels, change from baseline in quality of life as assessed by the Functional Assessment of Chronic Illness Therapy Fatigue scale, proportion of patients with breakthrough hemolysis, and proportion of patients with stabilized hemoglobin levels. Although ALXN1210 did not achieve superiority to eculizumab, Alexion reports that numeric results for all 6 end points favored ALXN1210.
The company plans to submit applications for approval of the drug to regulators in Japan, the United States, and the European Union by the second half of 2018.
ALXN1210’s 8-week dosing schedule, compared with eculizumab’s 2-week dosing schedule, may present distinct benefits for patients. However, it is unclear at what cost those benefits may come; the brand name Soliris, also approved to treat generalized myasthenia gravis and atypical hemolytic uremic syndrome, costs more than $500,000 per patient per year and is among the costliest therapies in the world.
Biosimilars of eculizumab, which have the potential to reduce costs for both patients and the healthcare system, have been eagerly awaited, and Amgen is currently developing a biosimilar candidate. However, as reported in a recent paper1 in the American Journal of Hematology, even more drug makers are developing novel anti-C5 drugs:
Reference
1. Ristano AM, Marotta S. Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2018;93(4):564-577. doi: 10.1002/ajh.25016.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.